Competition & SPRQ-Nx Delay Looming — Barclays Turns Bearish on PacBio
Barclays downgrades PacBio to Underweight from Equal Weight, cuts price target to $1.50 citing competition and H1 2026 consumables slowdown ahead of SPRQ-Nx launch.
/ 897 items
#Healthcare↓
Helus Pharma's HLP004 Phase 2: Small Study, Promising but Limited Signals
Helus Pharma's (Cybin/HELP) HLP004 Phase 2 trial shows potential adjunctive benefits in GAD but small size, 39% remission, no approval, injection format, and Phase 3 years away limit broad claims.
Billion-Dollar Hearts: Tenaya and Alnylam Join Forces to Target Genetic Causes of Cardiovascular Disease
Tenaya Therapeutics partners with Alnylam to discover new genetic targets for heart disease treatments, potentially earning up to $1.13 billion in milestones.
BioXcel's Breakthrough: BXCL501 Shows Promise in Easing Opioid Withdrawal Symptoms
BioXcel Therapeutics announces positive Phase 2 results for BXCL501 in treating opioid withdrawal, showing better efficacy and tolerability than lofexidine amid the opioid crisis.
PepGen Faces FDA Partial Hold on FREEDOM2 DM1 Trial, Advances in Multiple Countries
PepGen announces FDA partial clinical hold on FREEDOM2-DM1 trial due to preclinical questions, while gaining clearance in South Korea, Australia, New Zealand.
Day One Biopharmaceuticals Stock Jumps on Renewed M&A Rumors
Day One Biopharmaceuticals shares surge 26% to $12.62 amid fresh speculation of a potential buyout.